Universal Influenza Vaccine
Universal influenza vaccine (Bifluagen™)
Influenza viruses undergo constant genetic and antigenic changes. They are responsible for seasonal influenza and constantly pose the threat of a pandemic outbreak. A universal influenza vaccine capable of providing a broad protection is greatly needed. The basic strategy for development of such a vaccine is to target the highly conserved antigen domains so that the immune responses generated against them can be broadly cross-protective.
This novel universal influenza vaccine candidate (Bifluagen™) utilizes the DDFNP technology to uniquely combine two highly conserved antigen domains derived from two separate surface proteins of influenza virus – M2e and a HA2 fragment. The combination provides a broader conserved antigen base and a greatly enhanced protection. It is self-assembled as nanoparticles in the bacterial expression system at a high yield. It is highly flexible and suitable for "plug-and-play" strategy for expanding spectrum of protection and emergency use. The prototype vaccine has gone through preclinical studies with demonstrated broad protection.
Influenza viruses undergo constant genetic and antigenic changes. They are responsible for seasonal influenza and constantly pose the threat of a pandemic outbreak. A universal influenza vaccine capable of providing a broad protection is greatly needed. The basic strategy for development of such a vaccine is to target the highly conserved antigen domains so that the immune responses generated against them can be broadly cross-protective.
This novel universal influenza vaccine candidate (Bifluagen™) utilizes the DDFNP technology to uniquely combine two highly conserved antigen domains derived from two separate surface proteins of influenza virus – M2e and a HA2 fragment. The combination provides a broader conserved antigen base and a greatly enhanced protection. It is self-assembled as nanoparticles in the bacterial expression system at a high yield. It is highly flexible and suitable for "plug-and-play" strategy for expanding spectrum of protection and emergency use. The prototype vaccine has gone through preclinical studies with demonstrated broad protection.